CD4 and neoplasm: HNSCC patients are characterized by systemic immunosuppression, exhibiting increased populations of regulatory T cells and CD34+ progenitor cells, which suppress CD8+ T cell- and CD4+ helper T cell-mediated immunity at the primary tumor site and are associated with a poorer prognosis [3,4,5,6].